Cabrera v. Cordis Corp.

945 F. Supp. 209, 1996 WL 653719
CourtDistrict Court, D. Nevada
DecidedSeptember 13, 1996
DocketCV-S-94-720-PMP(RJJ)
StatusPublished
Cited by6 cases

This text of 945 F. Supp. 209 (Cabrera v. Cordis Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cabrera v. Cordis Corp., 945 F. Supp. 209, 1996 WL 653719 (D. Nev. 1996).

Opinion

ORDER

PRO, District Judge.

Before the Court for consideration are Defendant Cordis Corporation’s Motions in Limine to Exclude the Testimony at Trial of Plaintiffs Experts Saul PuszMn, Ph.D. (# 142), Aristo Vojdani, Ph.D. (# 149), Nachman Brautbar, M.D. (# 146), and Pierre Blais, Ph.D. (# 144). Also before the Court is Plaintiffs Motion in Limine Limiting Dr. Joan Venes’ Testimony (# 130) and Plaintiffs Motion in Limine Precluding Admission of Defendant’s Exemplar into Evidence and Precluding Dr. Ratner’s Opinions Derived Therefrom, or in the Alternative, Request for F.R.E. 104 Hearing (# 124).

The foregoing Motions have been fully briefed. On August 1 and 6,1996, the Court conducted a hearing pursuant to F.R.E. 104(a) to determine whether or to what extent the opinions of each challenged expert is admissible under F.R.E. 702. Each of the foregoing experts, except Dr. Ratner, testified at the hearing.

I. Factual Background

In 1977, Plaintiff Laura Cabrera, then age 15, had a Cordis-HaMm ventriculoperitoneal brain shunt implanted in her head to relieve the pressure caused by the retention of cerebrospinal fluid resulting from a condition known as hydrocephalus. The brain shunt was manufactured by Defendant Cordis Corporation.

This is a products liability action wherein Cabrera claims that the Cordis-Hakim brain shunt is defective. Cabrera alleges causes of action for strict liability in tort, failure to warn, breach of express and implied warranties, breach of warranty of fitness for a particular purpose, failure to comply with the provisions of the Food, Drug and Cosmetics Act, misrepresentation, fraud/eoncealment, negligence per se (violation of NRS § 598.0917(5)-Deceptive Trade Practices), intentional and negligent infliction of emotional distress, negligent hiring and supervision, corporate negligence/vicarious liability, and general and special damages, including attorneys’ fees and punitive damages. Cabrera further alleges that the brain shunt was defectively designed and manufactured in that:

(1) Cordis failed to perform any long-term tests to determine the durability and bioeompatibility of the materials composing the device;
(2) Cordis failed to warn the recipients of the brain shunt that they had not performed long-term testing of the shunts and therefore were unaware of the adverse consequences of long-term implantation; and
(3) Cordis did not establish a tracking mechanism by which recipients of the brain shunt could be notified in the event of device failure and/or recall.

Additionally, Cabrera claims she is suffering from silicone toxicity because the silicone components of the brain shunt have caused her body to produce silicone antibodies. Cabrera contends that the silicone toxicity has caused her to suffer from a variety of autoimmune ailments such as allergies, chronic fatigue and Epstein-Barr Syndrome. Cabrera also contends that she faces possible death or brain damage if and when the brain shunt needs to be replaced or repaired.

II. The Daubert Test

Defendant Cordis’ Motions In Limine seek to exclude at trial the testimony of Cabrera’s proposed expert witnesses Puszkin, Vojdani, Brautbar and Blais under Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993).

Rule 702 of the Federal Rules of Evidence provides that

... If scientific, technical, or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training or education, may testify thereto in the form of an opinion or otherwise.

Under the Daubert analysis of F.R.E. 702, the trial court performs a “gatekeeping role,” which requires that the court satisfy itself that the proffered expert scientific testimony meets certain standards of reliability before *212 it is admitted. Daubert, 509 U.S. 595-97, 113 S.Ct. at 2798. The Daubert Court explained that in order to determine whether an expert’s proffered testimony communicates “scientific knowledge,” the trial court must assess “whether the reasoning or methodology underlying the testimony is scientifically valid.” Id. at 592-93, 113 S.Ct. at 2796.

The Daubert Court listed four nonexclusive factors the trial court is to consider in determining whether an expert’s testimony is based on reliable scientific knowledge: (1) whether the theory or method employed by the expert has gained general acceptance in the relevant scientific community; (2) whether the method has been subject to peer-review and publication; (3) whether the method employed can be and has been tested; and (4) whether the known or potential rate of error and the existence and maintenance of standards controlling the technique is acceptable. Id. at 591-95, 113 S.Ct. at 2796-97. The four factors enumerated are illustrative rather than exhaustive, and may not be equally applicable in every case. For example, where an expert has not conducted original research, but is offering an opinion based upon that expert’s survey of available literature, the last two factors may not apply at all. Daubert v. Merrell Dow Pharmaceuticals, Inc., 43 F.3d 1311, 1317 n. 4 (9th Cir.1995).

On remand from the United States Supreme Court, the Ninth Circuit Court of Appeals provided the following additional guidance to trial courts:

One very significant fact to be considered is whether the experts are proposing to testify about matters growing naturally and directly out of research they have conducted independent of the litigation, or whether they have developed their opinions expressly for purposes of testifying. That an experts testifies for money does not necessarily cast doubt on the reliability of his testimony, as few experts appear in court merely as an eleemosynaiy gesture. But in determining whether proposed expert testimony amounts to good science, we may not ignore the fact that a scientist’s normal workplace is the lab or the field, not the courtroom or the lawyer’s office. (Footnote omitted.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Neal-Lomax v. Las Vegas Metropolitan Police Department
574 F. Supp. 2d 1193 (D. Nevada, 2008)
Hallmark v. Eldridge
189 P.3d 646 (Nevada Supreme Court, 2008)
Alfred v. Mentor Corp.
479 F. Supp. 2d 670 (W.D. Kentucky, 2007)
Doerr v. Mobil Oil Corp.
811 So. 2d 1135 (Louisiana Court of Appeal, 2002)
In Re Breast Implant Litigation
11 F. Supp. 2d 1217 (D. Colorado, 1998)
Pick v. American Medical Systems, Inc.
958 F. Supp. 1151 (E.D. Louisiana, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
945 F. Supp. 209, 1996 WL 653719, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cabrera-v-cordis-corp-nvd-1996.